Cellular Therapy for Autoimmune Disease

Dr. Samik Basu joined Cabaletta in December 2019 and recently became Chief Scientific Officer, previously serving as Vice President of Preclinical Research and Translational Medicine. Before Cabaletta, he was Head of Translational Sciences at Adaptimmune Therapeutics, Plc, leading research on TCR-based adoptive immunotherapies. At Merck Research Laboratories, he co-led preclinical development for Keytruda (pembrolizumab). With over 15 years of industry and academic experience, Dr. Basu has held roles at the NIH, Albert Einstein College of Medicine, and the University of Pennsylvania. He earned his M.D. from Temple University and completed residency in Clinical Pathology. Dr. Basu chairs the Clinical Immunology Committee of the American Association of Immunologists and has authored over 15 peer-reviewed articles.

Dr. Jinmin Lee joined Cabaletta in November 2019 and currently serves as the Head of Cellular and Molecular Immunology at Cabaletta, where she leads preclinical research efforts on developing cell therapies for autoimmune diseases. Prior to joining Cabaletta, her research focused on cell therapy for targeted depletion of autoreactive B cells in autoimmune diseases, and fundamental B cell biology including mechanisms of naive and memory B cell activation. She has over 10 years of industry and academic experience in cellular immunology, cell therapy, and autoimmunity with prior roles at the National Institutes of Health and the University of Pennsylvania. Dr. Lee earned her Ph.D. degree in Immunology from Cornell University, followed by postdoctoral training at the National Institute of Allergy and Infectious Diseases and the University of Pennsylvania.